Prostate Cancer Research Today is a free monthly online journal that collates and summarizes the latest research about Prostate Cancer, including details on symptoms, genetics, screening, treatment, information.

Volume 1 (2004), Issue 4 (November)

1. Alcohol consumption and risk of prostate cancer in middle-aged men.
   Int J Cancer, 113(1): 133-40. [Abstract] [Full-text]
2. Endorectal MR imaging and MR spectroscopic imaging for locally recurrent prostate cancer after external beam radiation therapy: preliminary experience.
   Radiology, 233(2): 441-8. [Abstract] [Full-text]
3. A prostate-specific membrane antigen-targeted monoclonal antibody-chemotherapeutic conjugate designed for the treatment of prostate cancer.
   Cancer Res, 64(21): 7995-8001. [Abstract] [Full-text]
4. Analysis of Wnt gene expression in prostate cancer: mutual inhibition by WNT11 and the androgen receptor.
   Cancer Res, 64(21): 7918-26. [Abstract] [Full-text]
5. Antiproliferative effect of liver X receptor agonists on LNCaP human prostate cancer cells.
   Cancer Res, 64(21): 7686-9. [Abstract] [Full-text]
6. Androgenic suppression of ATP-binding cassette transporter A1 expression in LNCaP human prostate cancer cells.
   Cancer Res, 64(21): 7682-5. [Abstract] [Full-text]
7. Nanoparticle-aptamer bioconjugates: a new approach for targeting prostate cancer cells.
   Cancer Res, 64(21): 7668-72. [Abstract] [Full-text]
8. Gene silencing in androgen-responsive prostate cancer cells from the tissue-specific prostate-specific antigen promoter.
   Cancer Res, 64(21): 7661-3. [Abstract] [Full-text]
9. PTEN up-regulates the tumor metastasis suppressor gene Drg-1 in prostate and breast cancer.
   Cancer Res, 64(21): 7655-60. [Abstract] [Full-text]
10. Randomised phase III study of intravenous vinorelbine plus hormone therapy versus hormone therapy alone in hormone-refractory prostate cancer.
    Ann Oncol, 15(11): 1613-21. [Abstract] [Full-text]
11. Effect of oral sucralfate on late rectal injury associated with radiotherapy for prostate cancer: A double-blind, randomized trial.
    Int J Radiat Oncol Biol Phys, 60(4): 1088-97. [Abstract] [Full-text]
12. Both pretreatment prostate-specific antigen level and posttreatment biochemical failure are independent predictors of overall survival after radiotherapy for prostate cancer.
    Int J Radiat Oncol Biol Phys, 60(4): 1082-7. [Abstract] [Full-text]
13. Do differences in target volume definition in prostate cancer lead to clinically relevant differences in normal tissue toxicity?
    Int J Radiat Oncol Biol Phys, 60(4): 1076-81. [Abstract] [Full-text]
14. Longitudinal assessment of changes in sexual function and bother in patients treated with external beam radiotherapy or brachytherapy, with and without neoadjuvant androgen ablation: data from CaPSURE.
    Int J Radiat Oncol Biol Phys, 60(4): 1066-75. [Abstract] [Full-text]
15. The GETUG 70 Gy vs. 80 Gy randomized trial for localized prostate cancer: feasibility and acute toxicity.
    Int J Radiat Oncol Biol Phys, 60(4): 1056-65. [Abstract] [Full-text]
16. Use of MRI and spectroscopy in evaluation of external beam radiotherapy for prostate cancer.
    Int J Radiat Oncol Biol Phys, 60(4): 1047-55. [Abstract] [Full-text]
17. PSA failure and the risk of death in prostate cancer patients treated with radiotherapy.
    Int J Radiat Oncol Biol Phys, 60(4): 1040-6. [Abstract] [Full-text]
18. Rectal bleeding after hypofractionated radiotherapy for prostate cancer: correlation between clinical and dosimetric parameters and the incidence of grade 2 or worse rectal bleeding.
    Int J Radiat Oncol Biol Phys, 60(4): 1033-9. [Abstract] [Full-text]
19. High conformality radiotherapy in Europe: thirty-one centres participating in the quality assurance programme of the EORTC prostate trial 22991.
    Eur J Cancer, 40(16): 2411-6. [Abstract] [Full-text]
20. On the mechanism of cell lysis by deformation.
    J Biomech, 38(1): 117-24. [Abstract] [Full-text]
21. Targeting multiple signaling pathways as a strategy for managing prostate cancer: multifocal signal modulation therapy.
    Integr Cancer Ther, 3(4): 349-80. [Abstract] [Full-text]
22. The role of intracellular pH in cell growth arrest induced by ATP.
    Am J Physiol Cell Physiol, 287(6): C1733-46. [Abstract] [Full-text]
23. Phase II study of oral bis (aceto) ammine dichloro (cyclohexamine) platinum (IV) (JM-216, BMS-182751) given daily x 5 in hormone refractory prostate cancer (HRPC).
    Invest New Drugs, 23(1): 79-84. [Abstract] [Full-text]
24. Possible synergistic prostate cancer suppression by anatomically discrete pomegranate fractions.
    Invest New Drugs, 23(1): 11-20. [Abstract] [Full-text]
25. Gluthatione-S-transferase P1 polymorphism I105V in familial and sporadic prostate cancer.
    Cancer Genet Cytogenet, 155(1): 82-6. [Abstract] [Full-text]
26. Sensitivity of prostate tumors to wild type and M protein mutant vesicular stomatitis viruses.
    Virology, 330(1): 34-49. [Abstract] [Full-text]
27. Double transfection improves small interfering RNA-induced thrombin receptor (PAR-1) gene silencing in DU 145 prostate cancer cells.
    FEBS Lett, 577(1): 175-80. [Abstract] [Full-text]
28. Genistein induces Gadd45 gene and G2/M cell cycle arrest in the DU145 human prostate cancer cell line.
    FEBS Lett, 577(1): 55-9. [Abstract] [Full-text]
29. Suitability of prostate cancer education materials: applying a standardized assessment tool to currently available materials.
    Patient Educ Couns, 55(2): 275-80. [Abstract] [Full-text]
30. Hypermethylation of the CpG islands in the promoter region of the GSTP1 gene in prostate cancer: a useful diagnostic and prognostic marker?
    Clin Chim Acta, 350(1): 181-8. [Abstract] [Full-text]
31. Human prostate cancer risk factors.
    Cancer, 101(10): 2371-490. [Abstract] [Full-text]
32. Quality of life impact of three different doses of suramin in patients with metastatic hormone-refractory prostate carcinoma: results of Intergroup O159/Cancer and Leukemia Group B 9480.
    Cancer, 101(10): 2202-8. [Abstract] [Full-text]
33. Theory about heuristic strategies based on verbal protocol analysis: the emperor needs a shave.
    Med Decis Making, 24(6): 681-6; author reply 687. [Abstract] [Full-text]
34. The application of the heuristic-systematic processing model to treatment decision making about prostate cancer.
    Med Decis Making, 24(6): 573-83. [Abstract] [Full-text]
35. Androgen receptor is targeted to distinct subcellular compartments in response to different therapeutic antiandrogens.
    Clin Cancer Res, 10(21): 7392-401. [Abstract] [Full-text]
36. Genetic analysis of the RNASEL gene in hereditary, familial, and sporadic prostate cancer.
    Clin Cancer Res, 10(21): 7150-6. [Abstract] [Full-text]
37. The influence of androgen deprivation therapy on dihydrotestosterone levels in the prostatic tissue of patients with prostate cancer.
    Clin Cancer Res, 10(21): 7121-6. [Abstract] [Full-text]
38. Pro PSA : a "pro cancer" form of PSA?
    Med Hypotheses, 64(1): 92-5. [Abstract] [Full-text]
39. The relationship between interleukin-6 and C-reactive protein in patients with benign and malignant prostate disease.
    Br J Cancer, 91(10): 1755-7. [Abstract] [Full-text]
40. Clusterin overexpression in both malignant and nonmalignant prostate epithelial cells induces cell cycle arrest and apoptosis.
    Br J Cancer, 91(10): 1842-50. [Abstract] [Full-text]
41. Integrin signaling links protein kinase Cepsilon to the protein kinase B/Akt survival pathway in recurrent prostate cancer cells.
    Oncogene, 23(53): 8659-72. [Abstract] [Full-text]
42. Substrates of the prostate-specific serine protease prostase/KLK4 defined by positional-scanning peptide libraries.
    Prostate, 62(1): 1-13. [Abstract] [Full-text]
43. Diagnostic validity of macrophage migration inhibitory factor in serum of patients with prostate cancer: a re-evaluation.
    Prostate, 62(1): 34-9. [Abstract] [Full-text]
44. Characterization of prostatic neuroendocrine cell line established from neuroendocrine carcinoma of transgenic mouse allograft model.
    Prostate, 62(1): 40-8. [Abstract] [Full-text]
45. Antinuclear autoantibodies in prostate cancer: immunity to LEDGF/p75, a survival protein highly expressed in prostate tumors and cleaved during apoptosis.
    Prostate, 62(1): 14-26. [Abstract] [Full-text]
46. Increased sensitivity of a metastatic model of prostate cancer to a novel tetravalent platinum analog.
    Prostate, 62(1): 91-100. [Abstract] [Full-text]
47. Inhibition of Wnt signaling downregulates Akt activity and induces chemosensitivity in PTEN-mutated prostate cancer cells.
    Prostate, 62(1): 61-8. [Abstract] [Full-text]
48. Combined external beam radiotherapy and Pd-103 brachytherapy boost improves biochemical failure free survival in patients with clinically localized prostate cancer: results of a matched pair analysis.
    Prostate, 62(1): 54-60. [Abstract] [Full-text]
49. Association of HER-2 polymorphism with Japanese sporadic prostate cancer susceptibility.
    Prostate, 62(1): 49-53. [Abstract] [Full-text]
50. Farnesyltransferase inhibitor effects on prostate tumor micro-environment and radiation survival.
    Prostate, 62(1): 69-82. [Abstract] [Full-text]
51. Transrectal ultrasound versus magnetic resonance imaging for detection of rectal wall invasion by prostate cancer.
    Prostate, 62(1): 101-4. [Abstract] [Full-text]
52. HER2/neu kinase-dependent modulation of androgen receptor function through effects on DNA binding and stability.
    Cancer Cell, 6(5): 517-27. [Abstract] [Full-text]
53. HER2/HER3 heterodimers in prostate cancer: Whither HER1/EGFR?
    Cancer Cell, 6(5): 427-8. [Abstract] [Full-text]
54. Sensitivity of treatment plan optimisation for prostate cancer using the equivalent uniform dose (EUD) with respect to the rectal wall volume parameter.
    Radiother Oncol, 73(2): 209-18. [Abstract] [Full-text]
55. Interpretation of expression-profiling results obtained from different platforms and tissue sources: examples using prostate cancer data.
    Eur J Cancer, 40(17): 2592-603. [Abstract] [Full-text]
56. Psychological effects of a suspicious prostate cancer screening test followed by a benign biopsy result.
    Am J Med, 117(10): 719-25. [Abstract] [Full-text]
57. Bleeding after transrectal ultrasonography-guided prostate biopsy: a study of 7-day morbidity after a six-, eight- and 12-core biopsy protocol.
    BJU Int, 94(7): 1014-20. [Abstract] [Full-text]
58. Determinants of long-term quality of life and voiding function of patients treated with radical prostatectomy or permanent brachytherapy for prostate cancer.
    BJU Int, 94(7): 1003-9. [Abstract] [Full-text]
59. A modified yeast assay used on archival samples of localized prostate cancer tissue improves the detection of p53 abnormalities and increases their predictive value.
    BJU Int, 94(7): 996-1002. [Abstract] [Full-text]
60. Evaluation of urinary extravasation and results after continence-preserving radical retropubic prostatectomy.
    BJU Int, 94(7): 991-5. [Abstract] [Full-text]
61. Testosterone therapy in the ageing male: what about the prostate?
    Andrologia, 36(6): 355-65. [Abstract] [Full-text]
62. Faecal calprotectin and lactoferrin as markers of acute radiation proctitis: a pilot study of eight stool markers.
    Scand J Gastroenterol, 39(11): 1113-8. [Abstract] [Full-text]
63. A community study using specified and unspecified scenarios to investigate men's views about PSA screening.
    Health Expect, 7(4): 274-89. [Abstract] [Full-text]
64. CXCL12-CXCR4 interactions modulate prostate cancer cell migration, metalloproteinase expression and invasion.
    Lab Invest, 84(12): 1666-76. [Abstract] [Full-text]
65. Telephone first post-intervention follow-up for men who have had radical radiotherapy to the prostate: evaluation of a novel service delivery approach.
    Eur J Oncol Nurs, 8(4): 325-33. [Abstract] [Full-text]
66. CYP3A4, CYP3A5, and CYP3A43 genotypes and haplotypes in the etiology and severity of prostate cancer.
    Cancer Res, 64(22): 8461-7. [Abstract] [Full-text]
67. Phosphatidylinositol 3'-kinase activation leads to multidrug resistance protein-1 expression and subsequent chemoresistance in advanced prostate cancer cells.
    Cancer Res, 64(22): 8397-404. [Abstract] [Full-text]
68. Evidence that TRPM8 is an androgen-dependent Ca2+ channel required for the survival of prostate cancer cells.
    Cancer Res, 64(22): 8365-73. [Abstract] [Full-text]
69. Bone morphogenetic protein (BMP)-6 signaling and BMP antagonist noggin in prostate cancer.
    Cancer Res, 64(22): 8276-84. [Abstract] [Full-text]
70. Skeletal morbidity in men with prostate cancer: quality-of-life considerations throughout the continuum of care.
    Eur Urol, 46(6): 731-39; discussion 739-40. [Abstract] [Full-text]
71. Systematic development of a guideline for early detection of prostate cancer: the German way in the evidence gap.
    Eur Urol, 46(6): 725-30. [Abstract] [Full-text]
72. Clinical consequences of screening for prostate cancer: 15 years follow-up of a randomised controlled trial in Sweden.
    Eur Urol, 46(6): 717-23; discussion 724. [Abstract] [Full-text]
73. Weekly docetaxel and vinorelbine (VIN-DOX) as first line treatment in patients with hormone refractory prostate cancer.
    Eur Urol, 46(6): 712-6. [Abstract] [Full-text]
74. Molecular biomarker in prostate cancer: the role of CpG island hypermethylation.
    Eur Urol, 46(6): 698-708. [Abstract] [Full-text]
75. Prostatic carcinoma causing urethral obstruction and obstipation in a cat.
    J Feline Med Surg, 6(6): 397-400. [Abstract] [Full-text]
76. A longitudinal analysis of the course of depressive symptomatology in geriatric patients with cancer of the breast, colon, lung, or prostate.
    Health Psychol, 23(6): 564-73. [Abstract] [Full-text]
77. Written emotional disclosure buffers the effects of social constraints on distress among cancer patients.
    Health Psychol, 23(6): 555-63. [Abstract] [Full-text]
78. Synthesis and in vitro testing of J591 antibody-dendrimer conjugates for targeted prostate cancer therapy.
    Bioconjug Chem, 15(6): 1174-81. [Abstract] [Full-text]
79. Fine-needle aspiration diagnosis of plasmacytoma presenting as breast masses in a patient on estrogen therapy for prostate cancer.
    Diagn Cytopathol, 31(6): 417-9. [Abstract] [Full-text]
80. Fibroblast growth factor 17 is over-expressed in human prostate cancer.
    J Pathol, 204(5): 578-86. [Abstract] [Full-text]
81. Regulation of the multidrug resistance transporter P-glycoprotein in multicellular prostate tumor spheroids by hyperthermia and reactive oxygen species.
    Int J Cancer, 113(2): 229-40. [Abstract] [Full-text]
82. Expression of prostate-specific antigen (PSA) and human glandular kallikrein 2 (hK2) in ileum and other extraprostatic tissues.
    Int J Cancer, 113(2): 290-7. [Abstract] [Full-text]
83. Prostate cancer screening, changing age-specific incidence trends and implications on familial risk.
    Int J Cancer, 113(2): 312-5. [Abstract] [Full-text]
84. Probing molecular interaction between concanavalin A and mannose ligands by means of SFM.
    Eur Biophys J, 33(7): 644-50. [Abstract] [Full-text]
85. Rarity of DNA sequence alterations in the promoter region of the human androgen receptor gene.
    Braz J Med Biol Res, 37(12): 1789-94. [Abstract] [Full-text]
86. Vitamin D3 inhibits fatty acid synthase expression by stimulating the expression of long-chain fatty-acid-CoA ligase 3 in prostate cancer cells.
    FEBS Lett, 577(3): 451-4. [Abstract] [Full-text]
87. Identification and functional analysis of consensus androgen response elements in human prostate cancer cells.
    Biochem Biophys Res Commun, 325(4): 1312-7. [Abstract] [Full-text]
88. Differences in health-related quality of life of prostate cancer patients based on stage of cancer.
    Psychooncology, 13(11): 800-7. [Abstract] [Full-text]
89. A statistical method for identifying differential gene-gene co-expression patterns.
    Bioinformatics, 20(17): 3146-55. [Abstract] [Full-text]
90. An ecologic study of prostate-specific antigen screening and prostate cancer mortality in nine geographic areas of the United States.
    Am J Epidemiol, 160(11): 1059-69. [Abstract] [Full-text]
91. Contemporary update of cancer control after radical prostatectomy in the UK.
    Br J Cancer, 91(11): 1853-7. [Abstract] [Full-text]
92. Treatment outcomes of three-dimensional conformal radiotherapy for localized prostate carcinoma: a large community-based experience.
    Cancer, 101(11): 2693-700. [Abstract] [Full-text]
93. Natural history of disease progression in patients who fail to achieve an undetectable prostate-specific antigen level after undergoing radical prostatectomy.
    Cancer, 101(11): 2549-56. [Abstract] [Full-text]
94. Analysis of subforms of free prostate-specific antigen in serum by two-dimensional gel electrophoresis: potential to improve diagnosis of prostate cancer.
    Clin Chem, 50(12): 2292-301. [Abstract] [Full-text]
95. Prostate depiction at endorectal MR spectroscopic imaging: investigation of a standardized evaluation system.
    Radiology, 233(3): 701-8. [Abstract] [Full-text]
96. Adenovirus-mediated FLT1-targeted proapoptotic gene therapy of human prostate cancer.
    Mol Ther, 10(6): 1059-70. [Abstract] [Full-text]
97. Targeting prostate cancer with conditionally replicative adenovirus using PSMA enhancer.
    Mol Ther, 10(6): 1051-8. [Abstract] [Full-text]
98. Prostate cancer: evaluation of vascular characteristics with dynamic contrast-enhanced T1-weighted MR imaging--initial experience.
    Radiology, 233(3): 709-15. [Abstract] [Full-text]
99. Increased endothelial uptake of paclitaxel as a potential mechanism for its antiangiogenic effects: potentiation by Cox-2 inhibition.
    Int J Cancer, 113(3): 490-8. [Abstract] [Full-text]
100. Lower levels of nuclear beta-catenin predict for a poorer prognosis in localized prostate cancer.
     Int J Cancer, 113(3): 415-22. [Abstract] [Full-text]
101. Sequence- and schedule-dependent enhancement of zoledronic acid induced apoptosis by doxorubicin in breast and prostate cancer cells.
     Int J Cancer, 113(3): 364-71. [Abstract] [Full-text]
102. Association of prostate cancer family history with histopathological and clinical characteristics of prostate tumors.
     Int J Cancer, 113(3): 471-4. [Abstract] [Full-text]
103. Racial disparity of epidermal growth factor receptor expression in prostate cancer.
     J Clin Oncol, 22(23): 4725-9. [Abstract] [Full-text]
104. Regression of mouse prostatic intraepithelial neoplasia by nonsteroidal anti-inflammatory drugs in the transgenic adenocarcinoma mouse prostate model.
     Clin Cancer Res, 10(22): 7727-37. [Abstract] [Full-text]
105. Associations between serum testosterone fall and cognitive function in prostate cancer patients.
     Clin Cancer Res, 10(22): 7575-82. [Abstract] [Full-text]
106. The use of real-time reverse transcription-PCR for prostate-specific antigen mRNA to discriminate between blood samples from healthy volunteers and from patients with metastatic prostate cancer.
     Clin Cancer Res, 10(22): 7511-9. [Abstract] [Full-text]
107. Preferential production of latent transforming growth factor beta-2 by primary prostatic epithelial cells and its activation by prostate-specific antigen.
     J Cell Physiol, 202(2): 361-70. [Abstract] [Full-text]

© 2004-2008 Prostate Cancer Research Today. All Rights Reserved.